Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03719300
- Locations
- 🇺🇸
American Institute of Research, Los Angeles, California, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Idaho Urologic Institute, PA, Meridian, Idaho, United States
Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
- Conditions
- Transitional Cell Carcinoma of Bladder
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT01878188
- Locations
- 🇮🇱
Tel Aviv Medical Center, Tel Aviv, Israel
🇮🇱Carmel Medical Center, Haifa, Israel
🇮🇱Bnai Zion MC, Haifa, Israel
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
- Conditions
- Pancreas, Adenocarcinoma
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01413087
- Locations
- 🇮🇱
Galil Maaravi, Nahariya, Israel
🇮🇱Meir Medical Center, Kfar Saba, Israel
🇮🇱Carmel Medical Center, Haifa, Israel
Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Biological: BC-819
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT00826150
- Locations
- 🇮🇱
The Edith Wolfson Medical Center, Holon, Israel
🇮🇱Hadassah University Hospital, Jerusalem, Israel
🇮🇱Meir Hospital, Kfar Saba, Israel
Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer
- Conditions
- Pancreatic Neoplasms
- Interventions
- Biological: DTA-H19
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT00711997
- Locations
- 🇮🇱
Meir Hospital, Kfar Saba, Israel
🇮🇱Hadassah University Hospital, Jerusalem, Israel
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
- Conditions
- Superficial Bladder Cancer
- Interventions
- Biological: BC-819/PEI
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT00595088
- Locations
- 🇺🇸
BCG Oncology, Phoenix, Arizona, United States
🇮🇱Meir Medical Center, Kfar Saba, Israel
🇮🇱Edith Wolfson Medical Center, Holon, Israel